Effects of combined sunitinib and extracranial stereotactic radiotherapy on bone marrow hematopoiesis

Johnny Kao, Jonathan Timmins, Junko Ozao-Choy, Stuart Packer

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

There is considerable interest in deploying stereotactic body radiotherapy in combination with immune therapy for patients with extracranial oligometastases. In addition to angiogenesis inhibition, sunitinib appears to mediate antitumor immunity through effects on circulating monocytic cells. The current study investigated the effects of combined sunitinib and stereotactic radiotherapy on hematopoiesis. As part of a phase I/II clinical trial utilizing concurrent sunitinib (25-50 mg on days 1-28) and image-guided radiation therapy (40-50 Gy in 10 fractions starting on days 8-19) for patients with metastatic cancer, the complete blood count, platelet count and automatic differential were performed pretreatment and on days 8 and 19. On average, sunitinib monotherapy for 7 days resulted in a 33% decrease in monocytes and an 18% decrease in neutrophils (P

Original languageEnglish (US)
Pages (from-to)2139-2144
Number of pages6
JournalOncology Letters
Volume12
Issue number3
DOIs
StatePublished - Sep 1 2016
Externally publishedYes

Fingerprint

Hematopoiesis
Radiotherapy
Bone Marrow
Image-Guided Radiotherapy
Phase II Clinical Trials
Clinical Trials, Phase I
Blood Cell Count
Radiosurgery
Platelet Count
Monocytes
Immunity
Neutrophils
Blood Platelets
sunitinib
Neoplasms
Therapeutics

Keywords

  • Hematopoiesis
  • Monocytes
  • Stereotactic radiotherapy
  • Sunitinib
  • Tumor immunology

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Effects of combined sunitinib and extracranial stereotactic radiotherapy on bone marrow hematopoiesis. / Kao, Johnny; Timmins, Jonathan; Ozao-Choy, Junko; Packer, Stuart.

In: Oncology Letters, Vol. 12, No. 3, 01.09.2016, p. 2139-2144.

Research output: Contribution to journalArticle

Kao, Johnny ; Timmins, Jonathan ; Ozao-Choy, Junko ; Packer, Stuart. / Effects of combined sunitinib and extracranial stereotactic radiotherapy on bone marrow hematopoiesis. In: Oncology Letters. 2016 ; Vol. 12, No. 3. pp. 2139-2144.
@article{2d56e3ceaec047e6adac012d5fac8928,
title = "Effects of combined sunitinib and extracranial stereotactic radiotherapy on bone marrow hematopoiesis",
abstract = "There is considerable interest in deploying stereotactic body radiotherapy in combination with immune therapy for patients with extracranial oligometastases. In addition to angiogenesis inhibition, sunitinib appears to mediate antitumor immunity through effects on circulating monocytic cells. The current study investigated the effects of combined sunitinib and stereotactic radiotherapy on hematopoiesis. As part of a phase I/II clinical trial utilizing concurrent sunitinib (25-50 mg on days 1-28) and image-guided radiation therapy (40-50 Gy in 10 fractions starting on days 8-19) for patients with metastatic cancer, the complete blood count, platelet count and automatic differential were performed pretreatment and on days 8 and 19. On average, sunitinib monotherapy for 7 days resulted in a 33{\%} decrease in monocytes and an 18{\%} decrease in neutrophils (P",
keywords = "Hematopoiesis, Monocytes, Stereotactic radiotherapy, Sunitinib, Tumor immunology",
author = "Johnny Kao and Jonathan Timmins and Junko Ozao-Choy and Stuart Packer",
year = "2016",
month = "9",
day = "1",
doi = "10.3892/ol.2016.4851",
language = "English (US)",
volume = "12",
pages = "2139--2144",
journal = "Oncology Letters",
issn = "1792-1074",
publisher = "Spandidos Publications",
number = "3",

}

TY - JOUR

T1 - Effects of combined sunitinib and extracranial stereotactic radiotherapy on bone marrow hematopoiesis

AU - Kao, Johnny

AU - Timmins, Jonathan

AU - Ozao-Choy, Junko

AU - Packer, Stuart

PY - 2016/9/1

Y1 - 2016/9/1

N2 - There is considerable interest in deploying stereotactic body radiotherapy in combination with immune therapy for patients with extracranial oligometastases. In addition to angiogenesis inhibition, sunitinib appears to mediate antitumor immunity through effects on circulating monocytic cells. The current study investigated the effects of combined sunitinib and stereotactic radiotherapy on hematopoiesis. As part of a phase I/II clinical trial utilizing concurrent sunitinib (25-50 mg on days 1-28) and image-guided radiation therapy (40-50 Gy in 10 fractions starting on days 8-19) for patients with metastatic cancer, the complete blood count, platelet count and automatic differential were performed pretreatment and on days 8 and 19. On average, sunitinib monotherapy for 7 days resulted in a 33% decrease in monocytes and an 18% decrease in neutrophils (P

AB - There is considerable interest in deploying stereotactic body radiotherapy in combination with immune therapy for patients with extracranial oligometastases. In addition to angiogenesis inhibition, sunitinib appears to mediate antitumor immunity through effects on circulating monocytic cells. The current study investigated the effects of combined sunitinib and stereotactic radiotherapy on hematopoiesis. As part of a phase I/II clinical trial utilizing concurrent sunitinib (25-50 mg on days 1-28) and image-guided radiation therapy (40-50 Gy in 10 fractions starting on days 8-19) for patients with metastatic cancer, the complete blood count, platelet count and automatic differential were performed pretreatment and on days 8 and 19. On average, sunitinib monotherapy for 7 days resulted in a 33% decrease in monocytes and an 18% decrease in neutrophils (P

KW - Hematopoiesis

KW - Monocytes

KW - Stereotactic radiotherapy

KW - Sunitinib

KW - Tumor immunology

UR - http://www.scopus.com/inward/record.url?scp=84979655855&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84979655855&partnerID=8YFLogxK

U2 - 10.3892/ol.2016.4851

DO - 10.3892/ol.2016.4851

M3 - Article

VL - 12

SP - 2139

EP - 2144

JO - Oncology Letters

JF - Oncology Letters

SN - 1792-1074

IS - 3

ER -